Perhaps the time taken to develop RC220, can be seen as a positive in that, RACE had enough time to get feedback from overseas KOLs, scientists, pharmas, to figure out which program would work and which doesn't. Wouldn't want RACE to run into a clinical trial, that doesn't work, or can't be executed.So, a lot of the feedback seems to have gone into making this strategic update.
Going over the presentation video, Damian seems very passionate about bringing bisantrene into market, for personal reasons too.
So, let's hope the new team, goes to great lengths to execute the mentioned trials with the right partnerships and agreements.
Ann: Race Strategic Update August 2023, page-68
-
- There are more pages in this discussion • 525 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.52 |
Change
-0.030(1.94%) |
Mkt cap ! $258.9M | |||
| Open | High | Low | Value | Volume |
| $1.57 | $1.57 | $1.50 | $75.34K | 49.79K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $1.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.52 | 49256 | 1 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |